Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.
Ora is the industry leader in both therapeutic experience and drug and device combination products that treat the diseases unique to the posterior segment. We have a dedicated Retina R&D team who focus solely on clinical model and endpoint development, and a site network including thriving retina practices in cities with a high prevalence of people with AMD and diabetic retina diseases. One of our novel endpoints is the Ora-VNC™ Mobility Course, which is used for the assessment of functional vision in patients with inherited retinal diseases. Watch the video below to hear from Keith Lane, Ora’s Posterior Segment Therapeutic Head, as he presents on addressing key challenges in standardized mobility testing and how our navigation courses have overcome these challenges to employ functional vision assessments as endpoints for clinical trials.
Standardized Mobility Testing for Assessment of Functional Vision in IRD
For more information visit www.oraclinical.com